Novo Nordisk
Novo’s Weight-Loss Drug Shows Better Lean Mass Preservation Than Lilly’s
Novo’s weight-loss drug has been found to preserve lean body mass better than Lilly’s, marking a significant advancement in obesity treatment options.
Eli Lilly’s Market Share Declines as Novo Nordisk Maintains Position
Eli Lilly’s market share is declining in India due to generic weight-loss drugs, while Novo Nordisk maintains a stable position amidst competition.
Ozempic Patent Expiry Sparks Weight-Loss Drug Surge in India
The expiry of Ozempic’s patent is set to revolutionize weight-loss drug availability in India, enabling more affordable options for patients.
Hims & Hers के शेयरों में 50% तेजी: Novo Nordisk के साथ साझेदारी
Hims & Hers के शेयरों में 50% की वृद्धि हुई है, जो Novo Nordisk के साथ साझेदारी का परिणाम है। जानें इसके पीछे की कहानी।